An innovation engine in sports medicine

What we focus on

Surgical-Fiberlock™ Technology

Revolutionizing surgical suturing
Our novel approach for soft tissue repair will allow the surgeon to attach patches and sutures in an easier and more reliable way. This technology has the potential to prevent suture cut throughs and easily augment weak tissue (e.g. torn rotator cuff tendons).

Broad range of indications
The Surgical-Fiberlock™ Technology can not only be applied in orthopedics but also shows huge potential for other indications such as minimal invasive or catheter based cardiovascular surgery.

Revolutionizing surgical suturing
Our novel approach for soft tissue repair will allow the surgeon to attach patches and sutures in an easier and more reliable way. This technology has the potential to prevent suture cut throughs and easily augment weak tissue (e.g. torn rotator cuff tendons).

Broad range of indications
The Surgical-Fiberlock™ Technology can not only be applied in orthopedics but also shows huge potential for other indications such as minimal invasive cardiovascular surgery.

BTB-Conversion Technology

The BTB-Conversion approach
Eight years of advanced biomaterial research and translational development at the University and ETH Zurich, in collaboration with leading Swiss surgeons, has led to ZuriMED’s Bone-Tendon-Bone(BTB)-Conversion Technology for knee ligament reconstruction.

BTB-Conversion™ Technology

The BTB-Conversion™ approach
Eight years of advanced biomaterial research and translational development at the University and ETH Zurich, in collaboration with leading Swiss surgeons, has led to ZuriMED’s Bone-Tendon-Bone(BTB)-Conversion™ Technology for knee ligament reconstruction.

Extracortical Fixation Technology

The single strand VariLoop™ for superior ligament fixation
Simple, easy to use, self flipping – truly knotless. Highly reliable and strong in all testing conditions. This implant can be used in different configurations in many indications where tension or compression is key for healing.

MagicBox for rapid button assembly onto open sutures
The first knotless button that can be intraoperatively mounted with ease. This technology opens the door to many new approaches where stitching a cortical fixation device to a tendon end was previously not possible.

MagicBox for rapid button assembly onto open sutures
The first knotless button that can be intraoperatively mounted with ease. This technology opens the door to many new approaches where stitching a cortical fixation device to a tendon end was previously not possible.

The single strand VariLoop™ for superior ligament fixation
Simple, easy to use, self flipping – truly knotless. Highly reliable and strong in all testing conditions. This implant can be used in different configurations in many indications where tension or compression is key for healing.

About ZuriMED Technologies AG

Innovation Engine in Sports Medicine

ZuriMED Technologies AG is an innovation-driven Swiss company based in Zurich that spun off in 2015 from the Institute for Biomechanics at ETH Zurich. ZuriMED excels as an innovation engine, driven by a dynamic management team and backed by a network of world-leading scientists, clinicians, and medical industry experts. ZuriMED’s strength lies in its ability to think outside the box and foster disruptive technologies that effectively tackle unmet clinical needs.

Board of Directors

Prof. Dr. Jess Snedeker
President of the Board of Directors

Dr. med. Dominique Tschudi
Vice-President Board of Directors

Prof. Dr. Robert Frigg
Member of Board of Directors

Ulrich Looser
Member of Board of Directors

Dr. Helen (Ying) Yang
Member of Board of Directors

Chan-Yuan Lu
Member of Board of Directors

Dr. Xiang Li
Member of Board of Directors

Team

Xiang Li
CEO
Dr. Sc. ETH Zurich

Elias Bachmann
CTO
MSc

Pol Banzet
Head of Development
MSc EPFL Lausanne

Sascha Brun
Head of Active Devices Development
MSc ETH Zurich

Andrea Möhl
Head of Clinical Affairs
MSc ETH Zurich

Sebastian Arevalo
Head of Quality
MSc

Ronja Senn
Head of Marketing and Sales
MSc ETH Zurich

Catherine Trojer Marcelo
Head of Finance
MA

Team

Mariano Perez Chaher
Supplier Quality Engineer
MSc

Ricardo Ribeiro
Quality Engineer
BSc ETH Zurich

Esteban Doig Cramer
R&D Engineer
BSc ETH Zurich

Carlota Sole Escobar
R&D Engineer
MSc

Esteban Ongini
R&D Project Manager
MSc ETH Zurich

Janick Eglauf
Market Development Manager
MSc ETH Zurich

Dominic Spothelfer
R&D Engineer
MSc

Cornelius Schlegel
R&D Engineer
MSc

Simon Zollinger
Senior R&D Project Manager
MSc ETH Zurich

Timo Looser
R&D Intern

History

Timeline

2023
2023

ZuriMED closes Series-A financing round & receives Innosuisse Swiss Accelerator Grant

The financing round was led by Chindex Medical Limited (Hong Kong), followed by Yellowstone Holding AG (Geneva) and a group of private investors that includes leading orthopaedic surgeons from Switzerland, Germany, France, and the United States. An additional non-diluting funding from Innosuisse will greatly expedite the development and regulatory registration process of a second clinical indication.

2022
2022

ZuriMED obtains Innosuisse Scale-up Award & Innosuisse Project Grant

Thanks to this award, ZuriMED can access the second phase of the Scale-up Coaching program to further accelerate the growth in Switzerland and the expansion into new global markets. The Project Grant supports the co-development with research partner University Hospital Balgrist on ZuriMED’s breakthrough technology for soft tissue repair.

2021
2021

ISO 13485 certificate obtained & First-in-man-study finished

ZuriMED gets ISO 13485 certified by BSI and the clinical trial run by the Balgrist University Hospital with 56 patients from July 2017 to June 2021, showing safety of the investigated device, has been completed.

2020
2020

ZuriMED closes a license deal with an international medical device company

One of ZuriMED’s endocortical fixation technologies for soft tissue repair has been licensed to an international medical device company. A strategic partnership has been established to work together to bring this technology to clinical applications.

2019
2019

ZuriMED obtains the Innosuisse Certificate

The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. The role of Innosuisse – the Swiss Innovation Agency – is to promote science-based innovation in the interests of industry and society in Switzerland.

2018
2018

Capital increase – loan conversion executed

Loan conversion of the seed round investment into equity.

 

 

2017
2017

Start of Innosuisse funded First-in-man study

Clinical trial on ZuriMED’s first product, the BTB-Converter™ was approved by Swissethics and sponsored by Innosuisse (formerly Commission for Technology and Innovation in Switzerland [CTI]).

2016
2016

Seed round investment received

Investment in terms of convertible loan. ZuriMED moves into the newly opened Balgrist Campus.

2015
2015

Incorporation of ZuriMED Technologies AG

Winner of Venture Kick Final, Switzerland’s largest start-up acceleration program. Presenting 2nd best business plan by >>venture>>, the leading competition for entrepreneurs in Switzerland, a joint initiative of ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse and EPFL.

News

Careers

We currently have no job openings

We are constantly on the lookout for bright talents, if you think you could be a good fit please send a spontaneous application to hr@zurimed.com.

Acknowledgements

ZuriMED Technologies AG
Lengghalde 5, 8008 Zurich, Switzerland
+41 44 552 12 28
info@zurimed.com

Disclaimer
The information contained in this website is for general information purposes only. Links taken to other websites are done so at visitors’ own risk and ZuriMED.com accepts no liability for any linked sites or their content.

LinkedIn